Advertisement

Topics

Revance Announces Pricing of Public Offering of Common Stock

08:30 EST 7 Dec 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of...

Other Sources for this Article

INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Burns McClellan, Inc.:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
MEDIA
General Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com

NEXT ARTICLE

More From BioPortfolio on "Revance Announces Pricing of Public Offering of Common Stock"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...